Measurable predictive factors for progression to AIDS among HIV-infected patients in Singapore

Annals of the Academy of Medicine Singapore

Volumn 34, Issue 1, 2005, Pages 84-89

  Chow, Khuan Yew ^a   Ang, L W ^b   Verghesse, I ^c   Chew, S K ^b   Leo, Y S ^c  

^a Health Promotion Board Singapore   (Singapore)

^b MINISTRY OF HEALTH   (Singapore)

^c NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

Author keywords

Age; AIDS; CD4 cell counts; HIV infection; Risk factors

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SINGAPORE; SURVIVAL;

EID: 15044352491     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Communicable Disease Centre. Communicable Disease Surveillance Report 2001. Singapore: Tan Tock Seng Hospital, 2001.
2. Carre N, Deveau C, Belanger F, Boufassa F, Persoz A, Jadand C, et al. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994;8:797-802.
3. Pezzotti P, Phillips AN, Dorrucci M, Lepri AC, Galai N, Vlahov D, et al. Category of exposure to HIV and age in the progression of AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996;313:583-6.
4. Multicohort Analysis Project Workshop. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. AIDS 1994;8:911-21.
5. Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. AIDS 1990;4:1059-66.
6. Rosenberg PS, Goedert JJ, Biggar RJ. Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994;8:803-10.
7. Mariotto AB. Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992;135:428-37.
8. Pezzotti P, Rezza G, Lazzarin A, Angarano G, Siniceo A, Aiuti F, et al. Influence of gender, age and transmission category on the progression from HIV seroconversion to AIDS. J Acquir Immune Defic Syndr 1992;5:745-7.
9. Rezza G, Dorrucci M, Pezzotti P, Lazzarin A, Angarano G, Siniceo A, et al. The seroconversion study on the natural history of HIV infection. In: Nicolosi A, editor. HIV Epidemiology. Models and Methods. New York: Raven Press, 1994:279-89.
10. Vella S, Giuliano M, Floridia M, Chiesi A, Tomino C, Seeber A, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995;9:51-6.
11. von Overbeck J, Egger M, Smith GD, Schoep M, Ledergerber B, Furrer H, et al. Survival in HIV infection: do sex and category of transmission matter? AIDS 1994;8:1307-13.
12. Eskild A, Magnus P, Sohlberg C, Jensen F, Kittelsen P. A comparison of the progression rate to acquired immunodeficiency syndrome between intravenous drug users and homosexual men. Scand J Soc Med 1994;4:309-14.
13. Operskalski EA, Stram DO, Lee H, Zhu Y, Donegan E, Busch MP, et al. Human immunodeficiency virus type 1 infection: relation of risk group and age to rate of progression to AIDS. J Infect Dis 1995;172:648-55.
14. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333: 751-6.
15. Veugelers PJ, Strathdee SA, Tindall B, Page KA, Moss AR, Schechter MT, et al. Increasing age is associated with faster progression to neoplasms but not opportunistic infections in HIV-infected homosexual men. AIDS 1994;8:1471-5.
16. Galai N, Vlahov D, Margolick JB, Chen K, Graham NM, Munoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drugs users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:66-74.
17. Jason J, Lui KJ, Ragni MV, Hessol NA, Darrow WW. Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men. JAMA 1989;261:725-7.
18. Giesecke J, Scalia-Tomba G, Berglund O, Berntorp E, Schulman S, Stigendal L. Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus. BMJ 1988;297:99-102.
19. Mindel A, Tenant-Flowers M. ABC of AIDS: natural history and management of early HIV infection. BMJ 2001;322:1290-3.
20. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(no.S-1):page nos?.
21. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
22. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992;6: 421-6.
23. Weinberg K, Parkman R. Age, the thymus and T lymphocytes, N Engl J Med 1995;332:182-3.
24. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4(+) T-lymphocytes regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
25. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
26. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
27. Munoz A, Carey V, Taylor JMG, Chmiel JS, Kingsley L, van Raden M, et al. Estimation of time since exposure for a prevalent cohort. Stat Med 1992;11:939-52.
28. Fahey JL, Taylor JM, Detels R, Hoffmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322: 166-72.
29. Kramer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, et al. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am J Epidemiol 1992;136:71-80.
30. Alcabes P, Schoenbaum EE, Klein RS. Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J Epidemiol 1993;137: 989-1000.
31. Rogers PA, Sinka KJ, Molesworth AM, Evans BG, Allardice GM. Survival after diagnosis of AIDS among adults resident in the United Kingdom in the era of multiple therapies. Commun Dis Public Health 2000;3:188-94.
32. del Amo J, del Romero J, Barrasa A, Perez-Hoyos S, Rodriguez C, Diez M, et al. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect 2002;78:255-60.
33. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women and men with AIDS. J Infec Dis 1992;166:74-9.
34. Alonso Socas M del M, Gomez Sirvent JL, Santolaria Fernandez F, Rodriguez Moreno F, Essardas H, Rodriguez Rodriguez E, et al. The efficacy of antiretroviral treatment in patients with human immunodeficiency virus infection. A study of 807 patients. (Spanish). Med Clin (Barc) 2000;115:481-6.
35. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
36. Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine Therapy in HIV infection. JAMA 1996;156,1073-7.
37. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994;39:387-94.
38. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Acquired Immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type-1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. Am J Epidemiol 1993;138:870-8.